Abstract:Canagliflozin alleviates remote liver injury in hypertensive rats through its antioxidant, anti‐inflammatory, anti‐lipogenic, and antiapoptotic properties. Canagliflozin is an antihypertensive and hepatoprotective drug rather than an antidiabetic. Hypertension (HTN) is a prevalent chronic disease. HTN and liver disease association is extensively noted. Thus, finding a medication that can alleviate HTN and its accompanying liver insult would be promising. This study investigated the potential impacts of canagliflozin "sodium–glucose cotransporter‐2 inhibitor" on the liver of the Nω‐nitro‐L‐arginine methyl ester (L‐NAME)‐induced HTN rat model. Twenty‐four adult male rats were divided into four groups; negative control group, canagliflozin group, L‐NAME group: 50 mg/kg of L‐NAME was injected daily for 5 weeks and L‐NAME + canagliflozin group: 1 week after L‐NAME injection both L‐NAME + canagliflozin (40 mg/kg) were given concomitantly daily for further 4 weeks. Liver functions, serum lipid profile, hepatic oxidative/nitrative stress biomarkers, gene expression of lipogenic enzymes, B‐cell lymphoma 2 (Bcl2), and DNA fragmentation, were measured. Besides, hepatic histology and immunohistochemistry of nuclear factor kappa B (NF‐κB) and endothelial nitric oxide synthase (eNOS) were assessed. Canagliflozin improved hepatic lipogenesis via the downregulation of fatty acid synthase (FAS) and transcriptional regulatory element binding protein 1c (SREBP1c) genes leading to an improved serum lipid profile. Further, canagliflozin modified the eNOS/inducible nitric oxide synthase (iNOS) pathway and decreased the NF‐κB immunoreactivity besides restoring the oxidants–antioxidants balance; increased reduced glutathione concomitant with declined malondialdehyde. This improvement of the liver was mirrored by the significant restoration of liver architecture and confirmed by the preserved liver DNA content and upregulation of the antiapoptotic Bcl2 mRNA level and attenuation of the alanine transaminase, aspartate aminotransferase. In conclusion, canagliflozin is a promising anti‐hypertensive and hepatic‐supportive medication. Research Highlights Canagliflozin's antioxidant, anti‐inflammatory, anti‐lipogenic, and antiapoptotic characteristics mitigate remote liver compromise caused by hypertension. Canagliflozin can be exploited as a hepatoprotective and antihypertensive medication.

Neuroprotective effect of canagliflozin against cisplatin-induced cerebral cortex injury is mediated by regulation of HO-1/PPAR-γ, SIRT1/FOXO-3, JNK/AP-1, TLR4/iNOS, and Ang II/Ang 1–7 signals

Canagliflozin protects against cisplatin-induced acute kidney injury by AMPK-mediated autophagy in renal proximal tubular cells

Canagliflozin Mitigated Cognitive Impairment in Streptozotocin-Induced Sporadic Alzheimer's Disease in Mice: Role of AMPK/SIRT-1 Signaling Pathway in Modulating Neuroinflammation

Empagliflozin protective effects against cisplatin-induced acute nephrotoxicity by interfering with oxidative stress and inflammation in Wistar rats

Evaluating the potential impact of sodium–glucose cotransporter‐2 inhibitor "canagliflozin" on the hepatic damage triggered by hypertension in rats

Neuroprotective effect of lansoprazole against cisplatin-induced brain toxicity: Role of Nrf2/ARE and Akt/P53 signaling pathways

Implication of M2 macrophage on NLRP3 inflammasome signaling in mediating the neuroprotective effect of Canagliflozin against methotrexate-induced cognitive impairment

Effect of tangeretin on cisplatin-induced oxido-inflammatory brain damage in rats

Canagliflozin Exerts Anti-Inflammatory Effects by Inhibiting Intracellular Glucose Metabolism and Promoting Autophagy in Immune Cells

An Effective Sodium-Dependent Glucose Transporter 2 Inhibition, Canagliflozin, Prevents Development of Hypertensive Heart Failure in Dahl Salt-Sensitive Rats

Canagliflozin Attenuates Lipotoxicity in Cardiomyocytes and Protects Diabetic Mouse Hearts by Inhibiting the Mtor/hif-1Α Pathway

Canagliflozin Attenuates Lipotoxicity in Cardiomyocytes and Protects Diabetic Mouse Hearts by Targeting the mTOR/HIF-1α Pathway

Curative Effect of AD-MSCs against Cisplatin-Induced Hepatotoxicity in Rats is Potentiated by Azilsartan: Targeting Oxidative Stress, MAPK, and Apoptosis Signaling Pathways

Canagliflozin Ameliorates Epithelial-Mesenchymal Transition in High-Salt Diet-Induced Hypertensive Renal Injury Through Restoration of Sirtuin 3 Expression and the Reduction of Oxidative Stress

SGLT2 Inhibitor Canagliflozin Alleviates High Glucose-Induced Inflammatory Toxicity in BV-2 Microglia

Ondansetron attenuates cisplatin-induced behavioral and cognitive impairment through downregulation of NOD-like receptor inflammasome pathway

Neuroprotective effects of Canagliflozin: Lessons from aged genetically diverse UM‐HET3 mice

Novel insights into the augmented effect of curcumin and liraglutide in ameliorating cisplatin-induced nephrotoxicity in rats: Effects on oxidative stress, inflammation, apoptosis and pyroptosis via GSK-3β

Cannabidiol Attenuates Cisplatin-Induced Nephrotoxicity by Decreasing Oxidative/nitrosative Stress, Inflammation, and Cell Death.

Canagliflozin, an SGLT2 inhibitor, attenuates the development of hepatocellular carcinoma in a mouse model of human NASH

Canagliflozin Ameliorates the Development of NAFLD by Preventing NLRP3-mediated Pyroptosis Through FGF21-ERK1/2 Pathway